Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06310304 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT06310304 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 24 participants.
The verdict
NCT06310304, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study is conducted to determine the Relative Bioavailability of Ruxolitinib XR Tablets Compared With Ruxolitinib IR Tablets Administered Orally in Healthy Participants.
Interventions
- DRUG Ruxolitinib IR
- DRUG Ruxolitinib XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-03-26 |
| Est. Completion | 2024-05-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06310304
The ClinicalTrials.gov registry entry for NCT06310304 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib IR is the first listed.
NCT06310304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06310304 about?
NCT06310304 is a clinical study titled "A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.". This study is conducted to determine the Relative Bioavailability of Ruxolitinib XR Tablets Compared With Ruxolitinib IR Tablets Administered Orally in Healthy Participants.
What is the current status of trial NCT06310304?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-03-26. Estimated completion is 2024-05-15.
What interventions are being tested in trial NCT06310304?
The interventions under investigation include: Ruxolitinib IR (DRUG), Ruxolitinib XR (DRUG).
Who is sponsoring clinical trial NCT06310304?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.